Search Results

You are looking at 151 - 160 of 372 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022

Featured Updates to the NCCN Guidelines

William G. Wierda, Jennifer Brown, Jeremy S. Abramson, Farrukh Awan, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Asher A. Chanan-Khan, Steve E. Coutre, Randall S. Davis, Herbert Eradat, Christopher D. Fletcher, Sameh Gaballa, Armin Ghobadi, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Brian Hill, Paul Kaesberg, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Anthony Mato, Claudio Mosse, Stephen Schuster, Tanya Siddiqi, Deborah M. Stephens, Chaitra Ujjani, Nina Wagner-Johnston, Jennifer A. Woyach, J. Christine Ye, Mary A. Dwyer, and Hema Sundar

Products, LP, Juno Therapeutics, Inc., Kite Pharma, Miragen Therapeutics, Inc., Oncternal Therapeutics, Inc., Pharmacyclics, Sunesis Pharmaceuticals, Inc., and Xencor, Inc. Jennifer Brown, MD, PhD, Panel Vice Chair, consulting fees from AbbVie, Inc

Full access

NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023

Featured Updates to the NCCN Guidelines

Al B. Benson III, Michael I. D’Angelica, Thomas Abrams, Daniel E. Abbott, Aijaz Ahmed, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, David Binder, Mitesh Borad, Christopher Bowlus, Daniel Brown, Adam Burgoyne, Jason Castellanos, Prabhleen Chahal, Jordan Cloyd, Anne M. Covey, Evan S. Glazer, William G. Hawkins, Renuka Iyer, Rojymon Jacob, Lawrence Jennings, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Sean Ronnekleiv-Kelly, Vaibhav Sahai, Gagandeep Singh, Stacey Stein, Anita Turk, Jean-Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole McMillian, Ryan Schonfeld, and Cindy Hochstetler

these individuals have been mitigated. Al B. Benson, III, MD, Panel Chair, has disclosed receiving grant/research support from AbbVie, Inc., Amgen Inc., Apexigen, Artemida Pharma, Cardiff Oncology, Elevar Therapeutics, Infinity Pharmaceuticals, Inc

Full access

NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021

Featured Updates to the NCCN Guidelines

Margaret von Mehren, John M. Kane III, Marilyn M. Bui, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, Jade Homsi, Vicki Keedy, Ciara M. Kelly, Edward Kim, David Liebner, Martin McCarter, Sean V. McGarry, Christian Meyer, Alberto S. Pappo, Amanda M. Parkes, I. Benjamin Paz, Ivy A. Petersen, Matthew Poppe, Richard F. Riedel, Brian Rubin, Scott Schuetze, Jacob Shabason, Jason K. Sicklick, Matthew B. Spraker, Melissa Zimel, Mary Anne Bergman, and Giby V. George

., Novartis Pharmaceuticals Corporation, Arog, Gradalis, and Spring Works Therapeutics. John M. Kane III, MD, Panel Vice Chair, has disclosed that he has no relevant financial relationships. Kristen N. Ganjoo, MD, Panel Member, has disclosed that she is a

Full access

NCCN Guidelines Insights: Breast Cancer, Version 3.2018

Featured Updates to the NCCN Guidelines

Matthew P. Goetz, William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, William B. Farrar, Sharon H. Giordano, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Melinda L. Telli, John H. Ward, Jessica S. Young, Dorothy A. Shead, and Rashmi Kumar

, Genentech, Inc., Merck & Co., Inc., OncoPep, Inc., and PharmaMar. He also has received consulting fees/honoraria from Genentech, Inc., Immunomedics, Inc., Myriad Genetic Laboratories, Inc., Hengrui Therapeutics, Inc., Mylan, and Puma Biotechnology, Inc

Full access

Toward Personalized Guidelines in Bladder Cancer

Peter E. Clark

targeted therapeutics. One challenge is that many of the oncogenic and tumor suppressive pathways that are disrupted are not currently targetable. Knowing what pathway has been altered is not enough. To truly take the next step in therapy, that pathway must

Full access

Cancer Immunology, Success Without Sequencing

William Blum

Therapeutics has a record-breaking $120 million in such funds to develop immunotherapies for cancer in cooperation with the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance and Memorial Sloan-Kettering Cancer Center. Of course, no real

Full access

The Need for United States–Based Guidelines for Myeloproliferative Neoplasms

Brady L. Stein, Susan O’Brien, Peter Greenberg, and Ruben A. Mesa

this high-risk but high-reward procedure. Finally, an unprecedented number of clinical trials have been performed evaluating novel therapeutics as single agents or in combination. As data mature, physicians will need guidance on how to incorporate such

Full access

Principles of Immunotherapy

Anthony J. Olszanski

“Immunotherapy has grabbed our attention [in oncology], and it is not the end of the story,” declared Anthony J. Olszanski, RPh, MD, Associate Professor, Director of the Phase I Developmental Therapeutics Program, and Director of the Medical

Full access

New Treatment Options for the Management of Multiple Myeloma

Shaji K. Kumar

/honoraria from Kesios Therapeutics, NOXXON Pharma AG, and SkylineDx. References 1. Durie BG Hoering A Abidi MH . Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma

Full access

Minimally Invasive Techniques for Treating Gynecologic Malignancies

Amanda N. Fader

Gynecologic Oncology and serves on the NCCN Cervical/Uterine/Vulvar Cancers Panel. Although MIS was initially used solely to aid in establishing a cancer diagnosis, it has now graduated to therapeutics, with various roles including staging, defining the